Dyne Therapeutics upsizes public stock offering
The biotechnology company expects gross proceeds of $375.15 million from the sale of 18.3 million shares.
Dyne Therapeutics (DYN), the biotechnology company, announced an upsized public offering of 18.3 million shares of common stock.
The company priced the shares at $20.50 per share.
Dyne expects gross proceeds of $375.15 million from the offering.